EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer

Weihong Zhang, Jing Qin, Jing Luo, Yanjuan Xiong, Fan Yang, Bin Li, Meng Shen, Huizhen Geng, Zibo Li, Xiao Tian, Shuzhan Li, Runmei Li und 6 weitere

Cancer Immunology, Immunotherapy · 11.03.2026 · 75 (4)

DOI: 10.1007/s00262-026-04338-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 11.03.2026. Verfasst von Weihong Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Biotherapy, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody therapy has been approved as second-line treatment for advanced non-small-cell lung cancer (NSCLC). Unfortunately, the objective response rate (ORR) is not satisfied. T lymphocytes obtained by co-culture with personalized tumor-specific antigenic peptide-pulsed dendritic cells (DC), also known as multiple target cytotoxic T lymphocytes (MCTL) can restore the antitumor immunity and potentially improve clinical outcomes. We conducted a clinical study evaluating MCTL immunotherapy combined with toripalimab in patients with advanced NSCLC.

Methods

This single-center, open-label, phase Ib trial (NCT04193098) evaluated the combination of MCTL and toripalimab as second-line therapy in 21 patients with advanced NSCLC. Peripheral blood samples were collected for antigenic peptide analysis, and patient immune status was assessed. The primary and secondary endpoints were to evaluate safety and clinical outcomes, respectively.

Results

Among the 21 patients, the ORR and disease control rate (DCR) were 33.3 and 76.2%, respectively. Median overall survival (mOS) was 24.1 months, and median progression-free survival (mPFS) was 8.6 months. Most patients demonstrated improved immune status post-treatment compared to baseline. Patients exhibiting pronounced immune enhancement following MCTL/toripalimab therapy tended to have better clinical outcomes. No significant adverse events (AEs) were observed during combination therapy.

Conclusion

In this cohort of patients with advanced NSCLC, MCTL/toripalimab therapy demonstrated manageable safety and promising antitumor efficacy as a second-line treatment. Further studies are warranted to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedCombined Modality TherapyDendritic CellsT-Lymphocytes, Cytotoxic

Stichwörter der Autor:innen

Combination therapyDendritic cellLung cancerMultiple target cytotoxic T lymphocytePD-1

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicaltoripalimab

Autor:innen und Institutionen

  • Department of Immunology and Biotherapy, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Can…
  • Hebei Bio-High Technology Development Co., Ltd., Shijiazhuang, Hebei, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Qin, J., Luo, J., Xiong, Y., Yang, F., Li, B., Shen, M., Geng, H., Li, Z., Tian, X., Li, S., Li, R., Wang, Y., Zhang, X., Ren, X., Sun, Q., Zhou, L., & Liu, L. (2026). A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 75(4). https://doi.org/10.1007/s00262-026-04338-7

Vancouver

Zhang W, Qin J, Luo J, Xiong Y, Yang F, Li B, et al. A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy. 2026;75(4). doi:10.1007/s00262-026-04338-7

BibTeX
@article{Zhang2026,
  author = {Zhang, Weihong and Qin, Jing and Luo, Jing and Xiong, Yanjuan and Yang, Fan and Li, Bin and Shen, Meng and Geng, Huizhen and Li, Zibo and Tian, Xiao and Li, Shuzhan and Li, Runmei and Wang, Yang and Zhang, Xinwei and Ren, Xiubao and Sun, Qian and Zhou, Li and Liu, Liang},
  title = {A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {4},
  doi = {10.1007/s00262-026-04338-7}
}
Kostenlos starten →